XML 48 R11.htm IDEA: XBRL DOCUMENT
v2.4.1.9

Avinza Co-Promotion | 3 Months Ended
--- | ---
Mar. 31, 2015
Co Promotion [Abstract] |
AVINZA Co-Promotion | Avinza Co-Promotion In 2003, the Company and Organon Pharmaceuticals USA Inc. ("Organon") entered into an agreement for the co-promotion of Avinza. Subsequently in 2006, the Company signed an agreement with Organon that terminated the Avinza co-promotion agreement between the two companies and returned Avinza co-promotion rights to the Company. In consideration of the early termination, the Company agreed to make quarterly royalty payments to Organon equal to 6.5% of Avinza net sales through December 31, 2012 and thereafter equal to 6.0% of Avinza net sales through patent expiration, currently anticipated to be November 2017. In January 2006, the Company and King Pharmaceuticals, now a subsidiary of Pfizer, entered into an agreement pursuant to which Pfizer acquired all of the Company’s rights in and to Avinza. Pfizer also assumed the Company’s co-promote termination obligation to make royalty payments to Organon based on net sales of Avinza. In connection with Pfizer's assumption of this obligation, Organon did not consent to the legal assignment of the co-promote termination obligation to Pfizer. Accordingly, the Company remains liable to Organon in the event of Pfizer's default of the obligation. Therefore, the Company recorded an asset as of February 26, 2007 to recognize Pfizer's assumption of the obligation, while continuing to carry the co-promote termination liability in the Company's consolidated financial statements to recognize the Company’s legal obligation as primary obligor to Organon. This asset represents a non-interest bearing receivable for future payments to be made by Pfizer and is recorded at its fair value. The receivable and liability will remain equal, and are adjusted each reporting period for changes in the fair value of the obligation including for any changes in the estimate of future net Avinza product sales. This receivable will be assessed on a quarterly basis or when a triggering event occurs for impairment (e.g. in the event Pfizer defaults on the assumed obligation to pay Organon). On a quarterly basis, management reviews the carrying value of the co-promote termination liability. In February 2014, Actavis launched a generic form of Avinza which resulted in a significant decrease in estimates of future net sales used to value the co-promote termination asset and liability. Due to assumptions and judgments inherent in determining the estimates of future net Avinza sales through November 2017, the actual amount of net Avinza sales used to determine the current fair value of the Company’s co-promote termination asset and liability may be materially different from current estimates. A summary of the co-promote termination liability as of March 31, 2015 is as follows (in thousands):
Net present value of payments based on estimated future net Avinza product sales as of December 31, 2014 | $ | 322 |
Assumed payments made by Pfizer or assignee | (297 | )
Fair value adjustments | 63 |
Total co-promote termination liability as of March 31, 2015 | $ | 88 |

X
- Details
Name: | lgnd_CoPromotionAbstract
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for AVINZA co promotion. + References No definition available. + Details
Name: | lgnd_CoPromotionDisclosureTextBlock
Namespace Prefix: | lgnd_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration